

# Naga Vara Kishore Pillarsetty

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3233738/publications.pdf>

Version: 2024-02-01

55  
papers

1,554  
citations

430442

18  
h-index

329751

37  
g-index

58  
all docs

58  
docs citations

58  
times ranked

2315  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells. <i>Translational Oncology</i> , 2022, 15, 101265.	1.7	8
2	Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1401-1407.	2.8	21
3	Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity. <i>Clinical Cancer Research</i> , 2022, 28, 1391-1401.	3.2	19
4	Noninvasive Imaging of CD4+ T Cells in Humanized Mice. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 658-666.	1.9	3
5	Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00898.	1.1	0
6	Synthesis of 124I-labeled epichaperome probes and assessment in visualizing pathologic protein-protein interaction networks in tumor bearing mice. <i>STAR Protocols</i> , 2022, 3, 101318.	0.5	2
7	The Impact of PIK3R1 Mutations and Insulin-PI3K Glycolytic Pathway Regulation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3603-3617.	3.2	7
8	Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	17
9	Predicting Gemcitabine Delivery by <sup>18</sup> F-FAC PET in Murine Models of Pancreatic Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 195-200.	2.8	6
10	A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking. <i>Biomaterials</i> , 2021, 269, 120630.	5.7	27
11	<sup>131</sup> I-Tocotrienol-Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs. <i>Journal of Nuclear Medicine</i> , 2021, 62, 584-590.	2.8	6
12	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2642-2651.	3.3	26
13	Applications of nuclear-based imaging in gene and cell therapy: Probe considerations. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 447-458.	2.0	13
14	Rapid detection of SARS-CoV-2 using a radiolabeled antibody. <i>Nuclear Medicine and Biology</i> , 2021, 98-99, 69-75.	0.3	2
15	PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. <i>Molecular Pharmaceutics</i> , 2021, 18, 3418-3428.	2.3	16
16	Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. <i>Nature Communications</i> , 2021, 12, 4669.	5.8	19
17	ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2026-2034.	1.9	10
18	Imaging of Cancer <sup>131</sup> I-Secretase Activity Using an Inhibitor-Based PET Probe. <i>Clinical Cancer Research</i> , 2021, 27, 6145-6155.	3.2	8

#	ARTICLE	IF	CITATIONS
19	Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. <i>Communications Biology</i> , 2021, 4, 1333.	2.0	11
20	Imaging Sigma-1 Receptor (S1R) Expression Using Iodine-124-Labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([ <sup>124</sup> I]IPAG). <i>Molecular Imaging and Biology</i> , 2020, 22, 358-366.	1.3	8
21	A Chemical Biology Approach to the Chaperome in Cancer—HSP90 and Beyond. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a034116.	2.3	32
22	Alpha radioimmunotherapy using <sup>225</sup> Ac-proteus-DOTA for solid tumors - safety at curative doses. <i>Theranostics</i> , 2020, 10, 11359-11375.	4.6	26
23	The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology. <i>Cancers</i> , 2020, 12, 2712.	1.7	4
24	Oncology-Inspired Treatment Options for COVID-19. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1720-1723.	2.8	15
25	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5178-5187.	3.2	18
26	A one-pot radiosynthesis of [ <sup>18</sup> F]PARPi. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2020, 63, 419-425.	0.5	6
27	Improved radiosynthesis of <sup>123</sup> I-MAPI, an auger theranostic agent. <i>International Journal of Radiation Biology</i> , 2020, , 1-7.	1.0	13
28	The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction. <i>Nature Communications</i> , 2020, 11, 319.	5.8	46
29	Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2020, 15, e0231745.	1.1	7
30	Measuring Tumor Epichaperome Expression Using [ <sup>124</sup> I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1414-1424.	1.5	13
31	Synthesis of the PET Tracer <sup>124</sup> I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1845-1850.	2.8	5
32	Fifty Years of Radiopharmaceuticals. <i>Journal of Nuclear Medicine Technology</i> , 2020, 48, 34S-39S.	0.4	4
33	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. <i>Cancer Cell</i> , 2019, 36, 559-573.e7.	7.7	40
34	A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. <i>Nuclear Medicine and Biology</i> , 2019, 71, 32-38.	0.3	34
35	Target engagement imaging of PARP inhibitors in small-cell lung cancer. <i>Nature Communications</i> , 2018, 9, 176.	5.8	75
36	<sup>18</sup> F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model. <i>EJNMMI Research</i> , 2018, 8, 53.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Leveraging PET to image folate receptor $\pm$ therapy of an antibody-drug conjugate. EJNMMI Research, 2018, 8, 87.	1.1	12
38	TMSOTf assisted synthesis of 2 $\alpha$ -deoxy-2 $\beta$ -[18F]fluoro- $\beta$ -D-arabinofuranosylcytosine ([18F]FAC). PLoS ONE, 2018, 13, e0196784.	1.1	3
39	Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Molecular Imaging and Biology, 2017, 19, 944-951.	1.3	7
40	In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2-deoxy-2-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models. Molecular Imaging and Biology, 2017, 19, 885-892.	1.3	14
41	Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. EJNMMI Research, 2017, 7, 95.	1.1	58
42	Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PUH71. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 129-132.	0.5	17
43	The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature, 2016, 538, 397-401.	13.7	233
44	Copper-64 labeled liposomes for imaging bone marrow. Nuclear Medicine and Biology, 2016, 43, 781-787.	0.3	25
45	Synthesis and evaluation of an 18 F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas. Nuclear Medicine and Biology, 2016, 43, 606-611.	0.3	12
46	<sup>18</sup> F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry. Bioconjugate Chemistry, 2016, 27, 298-301.	1.8	127
47	Radioiodinated PARP1 tracers for glioblastoma imaging. EJNMMI Research, 2015, 5, 123.	1.1	48
48	Synthesis and evaluation of 18F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression. European Journal of Medicinal Chemistry, 2014, 86, 769-781.	2.6	9
49	Influence of free fatty acids on glucose uptake in prostate cancer cells. Nuclear Medicine and Biology, 2014, 41, 254-258.	0.3	9
50	Development of a minimal saponin vaccine adjuvant based on QS-21. Nature Chemistry, 2014, 6, 635-643.	6.6	68
51	An improved strategy for the synthesis of [18F]-labeled arabinofuranosyl nucleosides. Nuclear Medicine and Biology, 2012, 39, 1182-1188.	0.3	10
52	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology, 2011, 7, 818-826.	3.9	240
53	2-18F-Fluoropropionic Acid as a PET Imaging Agent for Prostate Cancer. Journal of Nuclear Medicine, 2009, 50, 1709-1714.	2.8	31
54	Synthesis and Biological Evaluation of a Fluorine-18 Derivative of Dasatinib. Journal of Medicinal Chemistry, 2007, 50, 5853-5857.	2.9	38

#	ARTICLE	IF	CITATIONS
55	Synthesis and Evaluation of [18F] Labeled Pyrimidine Nucleosides for Positron Emission Tomography Imaging of Herpes Simplex Virus 1 Thymidine Kinase Gene Expression. Journal of Medicinal Chemistry, 2006, 49, 5377-5381.	2.9	19